Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T12:05:28.737Z.
Calculation as of: 2026-10-06T12:05:28.737Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a397cd850420951a0c9724a6b76f21fabdb26d17d869f1b33831b183cdf643d3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$2.37M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.47M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.59M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Autonomix Medical, Inc. (AMIX) | $1.92M | N/A | N/A | N/A | N/A |
| Curis, Inc. (CRIS)vs › | $1.54M | N/A | 341.73x | 341.73x | 341.73x |
| PMGC Holdings Inc. (ELAB)vs › | $1.49M | N/A | N/A | N/A | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.37M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.37M | N/A | N/A | N/A | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.47M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | N/A | N/A | N/A | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.59M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | N/A | 1.21x | 1.21x | 1.21x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
